| ABC | ATP-binding cassette |
| ADCC | Antibody-dependent cell-mediated cytotoxicity |
| ADC | Antibody-drug conjugate |
| ADMET | Absorption, Distribution, Metabolism, Excretion, and Toxicity |
| AML | Acute myeloid leukemia |
| AOC | Antibody oligonucleotide conjugate |
| cBu | Cyclobutane-1,1-dicarboxamide |
| CDR | Complementarity-determining region |
| CEA | Carcinoembryonic antigen |
| CH | Heavy chain constant domain |
| CL | Light chain constant domain |
| CPP-scFv | Cell-penetrating peptide single-chain variable fragment |
| DAR | Drug-Antibody ratio |
| DM1 | Mertansine |
| DXd | Deruxtecan |
| ECM | Extracellular matrix |
| EGFR | Epidermal growth factor receptor |
| Fab | Antigen-binding fragment |
| Fc | Crystallizable fragment |
| FcRn | Neonatal Fc receptor |
| Fv | Variable fragment of antibody |
| GCC | Guanylyl cyclase C |
| GSH | Glutathione |
| HCs | Heavy chains |
| HER2 | Human Epidermal Growth Factor Receptor 2 |
| H3-OPT | CDR-H3 optimization toolkit |
| HR | Homologous recombination |
| IC50 | Half-maximal inhibitory concentration |
| IgG | Immunoglobulin G |
| LC | Light chain |
| Lys-MCC-DM1 | Lysine-linked maytansinoid metabolite |
| mAb | Monoclonal antibody |
| MDR1 | Multidrug resistance protein 1 |
| MD | Molecular dynamics |
| MMAE | Monomethyl auristatin E |
| MSA | Multiple Sequence Alignment |
| NAMPT | Nicotinamide phosphoribosyltransferase |
| NHEJ | Non-homologous end joining |
| PABC | Para-aminobenzyl carbamate |
| PBD | Pyrrolobenzodiazepine |
| PEG | Polyethylene glycol |
| pLDDT | Predicted Local Distance Difference Test |
| PROTAC | Proteolysis Targeting Chimera |
| RAbD | RosettaAntibodyDesign |
| scFv | Single-chain variable fragment |
| SMCC | Succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate |
| STING | Stimulator of Interferon Genes |
| TAP | Therapeutic Antibody Profiler |
| T-DM1 | Trastuzumab emtansine |
| TME | Tumor microenvironment |
| VH | Variable heavy chain domain |
| VL | Variable light chain domain |